STOCK TITAN

Apimeds Pharmaceuticals US Reports Third Quarter 2026 Results, Delivers First Operating Revenue from Technology Services

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Apimeds Pharmaceuticals US (APUS) reported third-quarter 2026 revenue of $2.89 million in its first full quarter of revenue from its technology business. Revenue was zero a year earlier. Operating income was $2.0 million, and net income of $33.6 million included a $25.26 million unrealized gain on digital assets. Apimeds completed its transition to technology infrastructure by disposing of its former biopharmaceutical subsidiary on July 14, 2026.

The nine-month net loss was $21.6 million. At September 30, 2026, Apimeds held $17,912 in cash and $8.0 million in restricted cash. Its senior secured convertible note matures December 8, 2026, with $10.5 million in outstanding principal. Digital assets represented 93% of total assets. These conditions raise substantial doubt about Apimeds’ ability to continue operating. The company is pursuing capital raising and refinancing alternatives.

Loading...
Loading translation...
12 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

3 major · 9 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointThird-quarter revenue reached $2.89 million versus no revenue a year earlier, marking the first full quarter of technology revenue
  • Moderate pointThird-quarter operating income was $2.0 million
  • Moderate pointThird-quarter net income was $33.6 million, or $19.13 per basic share and $7.68 per diluted share, including a $25.26 million unrealized digital-asset gain
  • Moderate pointSubsidiary financing brought in $750,000 in October 2026 21% of market cap
  • Moderate pointTechnology business transition was completed with the July 14, 2026 disposal of the former biopharmaceutical subsidiary
  • Moderate pointBlockAssure agreement gives MindWave a two-year insurance infrastructure contract signed October 4, 2026
  • Moderate pointAQUAE Holdings agreement for climate finance infrastructure was signed by MindWave in September 2026
  • Moderate pointFlash Sports & Media Holdings agreement for sports media infrastructure was signed by MindWave in September 2026
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Bermuda joint venture with Skalup Capital gives MindWave a 75% stake in a venture to establish an insurance and technology business
3 minor points
  • Minor pointSoftware development and deployment services generated $2.48 million from two enterprise customers in the third quarter
  • Minor pointNine-month revenue was $3.2 million through September 30, 2026
  • Minor point. Forward-looking: it has not happened yet and may not happen.Recurring revenue is a company goal for contracted project work

Negative

  • Major pointSubstantial doubt about continued operations remains, and Apimeds is pursuing capital raising and refinancing alternatives
  • Major point. Forward-looking: it has not happened yet and may not happen.Senior secured convertible note with $10.5 million in outstanding principal matures December 8, 2026 2.9× market cap
  • Major pointNine-month net loss was $21.6 million, or $12.89 per share, reflecting transition-related costs earlier in 2026
  • Moderate pointDigital assets accounted for $142.4 million, or 93% of total assets, at September 30, 2026
  • Minor pointCash was $17,912 at September 30, 2026, with a separate $8.0 million in restricted cash
4 minor points
  • Minor pointGeneral and administrative expenses were $12.0 million for the nine months and $0.8 million for the third quarter
  • Minor pointRelated-party customer was one of two enterprise customers that received software development and deployment services in the third quarter
  • Minor point. Forward-looking: it has not happened yet and may not happen.Bermuda joint venture is subject to licensing by the Bermuda Monetary Authority
  • Minor pointThird-quarter cost of revenue was $54,300

News Explained

MindWave’s Bermuda joint-venture stake depends on licensing, while the subsidiary’s October financing has no stated form or terms.

MindWave, Apimeds’ wholly owned subsidiary, signed technology-services agreements with AQUAE Holdings and Flash Sports & Media Holdings in September 2026.

It also signed a two-year master agreement with BlockAssure on October 4, 2026, establishing signed project arrangements in climate finance, sports media and insurance infrastructure.

MindWave also entered a Bermuda insurance-and-technology joint venture with Skalup Capital, with MindWave holding 75% subject to licensing by the Bermuda Monetary Authority.

Separately, the company reports that its subsidiary received $750,000 in financing in October 2026. The release does not specify whether this financing is debt or equity, or provide repayment or dilution terms, so its effect on ownership and repayment obligations cannot be established from this disclosure.

Key Figures

Quarterly revenue: $2.89 million Software services revenue: $2.48 million Operating income: $2.0 million +5 more
Quarterly revenue
$2.89 million
Third quarter 2026; compared with no revenue in the third quarter of 2025
Software services revenue
$2.48 million
Delivered to two enterprise customers, one of which is a related party
Operating income
$2.0 million
Third quarter 2026
Net income
$33.6 million
Third quarter 2026; includes a $25.26 million unrealized gain on digital assets
Nine-month net loss
$21.6 million
Nine months ended September 30, 2026
Cash and restricted cash
$17,912 cash; $8.0 million restricted cash
At September 30, 2026
Digital assets
$142.4 million, or 93%
Share of total assets at September 30, 2026
Senior secured convertible note
$10.5 million outstanding principal
Matures December 8, 2026

Key Terms

discontinued operations, restricted cash, convertible note, going concern
4 terms
discontinued operations financial
"now reported as discontinued operations"
Discontinued operations are parts of a company that it has decided to sell or shut down, and no longer plans to run in the future. This matters to investors because it helps them understand which parts of the business are ongoing and which are being phased out, providing a clearer picture of the company’s current performance and future prospects. Think of it like a store closing a department—it no longer contributes to sales or profits.
restricted cash financial
"cash of $17,912 and restricted cash of $8.0 million"
Cash that a company holds but cannot use for day-to-day operations because it is set aside for a specific purpose—such as meeting loan covenants, serving as collateral, funding an escrow, or complying with regulations. Like money in a locked savings account earmarked for a bill, restricted cash reduces the cash available to run the business and pay dividends or debts, so investors treat it differently when assessing a company’s true short-term financial strength.
convertible note financial
"senior secured convertible note, with outstanding principal of $10.5 million"
A convertible note is a type of loan that a company gets from investors, which can later be turned into company shares instead of being paid back in cash. It matters because it helps startups raise money quickly without setting a fixed value for the company right away, making it easier to grow and attract investors.
going concern financial
"ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Quarterly revenue of $2.89 million and operating income of $2.0 million as the company completes its transition to a technology infrastructure business

MATAWAN, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), today reported financial results for the third quarter ended September 30, 2026, as filed in its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission.

Third Quarter 2026 Highlights

  • Revenue of $2.89 million, compared with no revenue in the third quarter of 2025, the Company’s first full quarter of revenue from its technology business.
  • $2.48 million from software development and deployment services delivered to two enterprise customers, one of which is a related party.
  • Operating income of $2.0 million for the quarter, on cost of revenue of $54,300 and general and administrative expenses of $0.8 million.
  • Net income of $33.6 million, or $19.13 per basic share and $7.68 per diluted share, which includes a $25.26 million unrealized gain on digital assets.
  • Total assets of $153.5 million and shareholders’ equity of $140.5 million at September 30, 2026.
  • Business transition completed with the disposal of the Company’s former biopharmaceutical subsidiary on July 14, 2026, now reported as discontinued operations.

Recent Business Developments

  • Enterprise client agreements: Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) operates through its wholly owned subsidiary MindWave Innovations Inc. (“MindWave”). MindWave signed technology services agreements with AQUAE Holdings for climate finance infrastructure and Flash Sports & Media Holdings for sports media infrastructure in September 2026, followed by a two-year master agreement with Delaware-based BlockAssure Inc. for insurance infrastructure on October 4, 2026.
  • Bermuda insurance joint venture: MindWave entered into a joint venture with Singapore-based Skalup Capital to establish an insurance and technology business in Bermuda, with MindWave holding 75%, subject to licensing by the Bermuda Monetary Authority.
  • Leadership: Eric Sherb was appointed Chief Financial Officer effective October 1, 2026.
  • Financing: The Company’s subsidiary received $750,000 in financing in October 2026.

“The third quarter marks a turning point for the Company, with our first meaningful revenue from technology services and operating income for the quarter,” said Dr. Vin Menon, Chief Executive Officer of MindWave.

“We have signed enterprise agreements across climate finance, sports media and insurance, all running on the same MindChain infrastructure. Our focus now is delivering those projects on schedule, converting contracted work into recurring revenue and strengthening our balance sheet.”

Nine-Month Results

For the nine months ended September 30, 2026, revenue was $3.2 million and the net loss was $21.6 million, or $12.89 per share, reflecting transition-related costs earlier in the year. General and administrative expenses for the period were $12.0 million.

Balance Sheet and Liquidity

On September 30, 2026, the Company held cash of $17,912 and restricted cash of $8.0 million. Digital assets represented $142.4 million, or 93%, of total assets. The Company’s senior secured convertible note, with outstanding principal of $10.5 million, matures on December 8, 2026. As disclosed in the Form 10-Q, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company is pursuing capital raising and refinancing alternatives. Investors are encouraged to review the full Form 10-Q, available at www.sec.gov.

About Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) operates through its wholly owned subsidiary, MindWave, which develops enterprise technology infrastructure and builds and operates dedicated networks for clients in climate finance, sports media, insurance and financial services.

About MindWave Innovations Inc.

MindWave develops enterprise blockchain infrastructure, including the MindChain network, and institutional platforms for regulated financial services, real-world asset digitization and enterprise applications. For more information, visit https://www.mindwaveinnovations.com/

Forward-Looking Statements

Certain statements and information in this earnings release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our expectations, beliefs, plans, financial prospects and guidance; financial or performance estimates and expectations (including estimated or expected revenues, earnings, operating income, timing of expenses, tax rates, acquisition amortization and cash flow) and expected drivers; impact of future efficiencies and cost savings; future capital allocation, including investments, capital expenditures and share repurchases, and expected drivers; strategies, priorities and opportunities for growth, including plans for, the delivery of client projects, future revenue, the Bermuda joint venture, capital raising and refinancing, and the Company’s business strategy. These statements are based on current expectations and are subject to risks and uncertainties, including the Company’s ability to continue as a going concern, to refinance or repay its senior secured note, to collect amounts due from customers, to regain and maintain compliance with NYSE American listing standards, and the volatility of the value of its digital assets, as well as the risks described in the Company’s filings with the SEC. Any information that is not historical in nature is subject to change. These statements are made on the basis of management’’ views and assumptions regarding future events and business performance as of the time the statements are made. The Company undertakes no obligation to update these statements except as required by law.

Actual results may differ materially. Such differences may result from actions taken by the Company, including restructuring or strategic initiatives (including capital investments, asset acquisitions or dispositions, new or expanded business lines or cessation of certain operations), our execution of our business plans, our ability to quickly execute on cost rationalization while preserving revenue, the discovery of additional information or other business decisions, as well as from developments beyond the Company’s control, including:

  • the occurrence of subsequent events;
  • deterioration in domestic and global economic conditions or failure of conditions to improve as anticipated;
  • international, including tariffs and other trade policies, political or military developments;
  • regulatory and legal developments; and
  • technological developments.

Additional factors are set forth in the Company’s most recent Annual Report on Form 10-K, including under the captions “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Business,” subsequent quarterly reports on Form 10-Q, including under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and subsequent filings with the Securities and Exchange Commission.

Media and Investor Relations MindWave Innovations Inc. contact@mindwaveinnovations.com

Corporate Communications:

IBN.Ai
Austin, Texas

www.IBN.Ai

512.354.7000 Office

Editor@IBN.Ai


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue and profit did Apimeds (APUS) report for Q3 2026?

Apimeds recorded $2.89 million in revenue, $2.0 million in operating income and $33.6 million in net income for the third quarter. It had no revenue in the year-earlier quarter. This quarter’s net income included a $25.26 million unrealized gain on digital assets.

Why did Apimeds (APUS) report substantial doubt about its ability to continue operating?

Apimeds faced limited cash and a December 8, 2026 debt maturity, with most of its assets held in digital assets. At September 30, 2026, it held $17,912 in cash and $8.0 million in restricted cash. The senior secured convertible note had $10.5 million in outstanding principal. Apimeds is pursuing capital raising and refinancing alternatives.

What license does the Apimeds (APUS) Bermuda joint venture need?

The joint venture is subject to licensing by the Bermuda Monetary Authority. Apimeds subsidiary MindWave entered into the venture with Skalup Capital to establish an insurance and technology business in Bermuda, with MindWave holding a 75% stake.

Keep reading